List of Amvuttra drug patents

Amvuttra is owned by Alnylam Pharms Inc.

Amvuttra contains Vutrisiran.

Amvuttra has a total of 12 drug patents out of which 0 drug patents have expired.

Amvuttra was authorised for market use on 13 June, 2022.

Amvuttra is available in solution;subcutaneous dosage forms.

Amvuttra can be used as amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Drug patent challenges can be filed against Amvuttra from 2026-06-13.

The generics of Amvuttra are possible to be released after 28 July, 2036.

AMVUTTRA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: 2026-06-13

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

64

United States

24

Japan

17

European Union

12

Canada

9

China

8

Israel

8

Australia

8

Korea, Republic of

7

Singapore

5

Mexico

5

Hong Kong

4

Chile

3

Denmark

3

Slovenia

3

Lithuania

3

Argentina

3

Croatia

3

Spain

EA

3

EA

2

South Africa

2

Russia

2

Hungary

2

Brazil

2

Portugal

2

Poland

2

Taiwan, Province of China

2

RS

2

India

2

Ukraine

2

New Zealand

1

Morocco

1

Philippines

1

Costa Rica

1

Colombia

1

Guatemala

1

Malaysia

1

Dominican Republic

1

Peru

1

Nicaragua

1

Ecuador

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic